Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Depressive Disorders

Ibogaine for Depressive Disorders

22 papers and 1 clinical trial exploring ibogaine as a treatment for depressive disorders.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationApproximately 260 million people worldwide are affected by depression.

Depressive Disorders

Depressive disorders, particularly major depressive disorder (MDD), are significant contributors to global mental health issues. Research into the therapeutic potential of psychedelics, such as psilocybin and ketamine, offers promising avenues for treatment, especially for cases that are resistant to conventional therapies.

Full Depressive Disorders profile

Academic Research

22 papers
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

Published
February 1, 2026
Journal
Journal of Affective Disorders
Authors
Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., Williams, N. R.
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Paywallindividual

The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation

This rodent study found that the nonhallucinogenic psychoplastogen tabernanthalog (TBG) promotes cortical neuroplasticity and sustained antidepressant effects through the same 5-HT2A, TrkB, mTOR, and AMPA receptor pathway as psychedelics, but without inducing the immediate glutamate burst or immediate early gene activation previously thought necessary for psychedelic-induced neuroplasticity.

Published
August 4, 2025
Journal
Nature Neuroscience
Authors
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Viswanathan, J., Barragan, E. V., Lozano, S. A., Seban, N., Powell, N. A., Chytil, M., Meyer, R., Rose, D., Hempel, C., Olson, D. E., Olson, E., Hansen, H. D., Madsen, C. A., Knudsen, G. M., Redd, C., Wheeler, D. G., Guanzon, N., Muir, J., Quon, G., McCorvy, J. D., Rasmussen, K., Liston, C., Gray, J. A., Heifets, B. D., Nord, A. S., Kim, C. K., Ghandi, S. P., Hennesssey, J. J., Hu, H., Ly, C.
Paywallindividual

Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury

This analysis of an open-label observational study (n=30) found that magnesium-ibogaine therapy in combat veterans with traumatic brain injury (TBI) led to slower brain wave patterns and reduced neural complexity on EEG, which correlated with improvements in PTSD, anxiety, and cognitive function at one-month follow-up.

Published
July 24, 2025
Journal
Nature Mental Health
Authors
Lissemore, J. I., Chaiken, A., Keller, C. J., Williams, N. R., Cherian, K. N., Buchanan, D., Espil, F., Keynan, J. N., Sridhar, M., Rolle, C. E., Saggar, M.
Open Accessindividual

Magnesium-ibogaine therapy in veterans with traumatic brain injuries

This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Published
January 5, 2024
Journal
Nature Medicine
Authors
Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., Keynan, O., Coetzee, J. P., Batail, J. M., Phillips, A., Bassa, N. J., Sahlem, G. L., Inzunza, J., Millar, T., Dickinson, J., Rol, C. E., Keller, J., Adamson, M., Kratter, I. H., Williams, N. R.

Clinical Trials

1 trial
CompletedPhase NA

Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

This observational cohort study (n=30) evaluated the safety and efficacy of Ibogaine-Magnesium Therapy in veterans with sequelae of repeated blast exposure.

Started
November 15, 2021
Type
observational
Blinding
none
Randomized
No
Registry ID
NCT04313712

Explore further

Search all Ibogaine papers Search all Depressive Disorders trials Full Ibogaine profile Full Depressive Disorders profile